Diversify Wealth Management LLC Takes $740,000 Position in Elevance Health, Inc. $ELV

Diversify Wealth Management LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,527 shares of the company’s stock, valued at approximately $740,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ELV. Sound View Wealth Advisors Group LLC raised its holdings in Elevance Health by 3.0% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock worth $354,000 after buying an additional 29 shares during the last quarter. Fulton Breakefield Broenniman LLC lifted its position in Elevance Health by 3.6% during the fourth quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock valued at $289,000 after purchasing an additional 29 shares during the period. Perigon Wealth Management LLC boosted its stake in shares of Elevance Health by 2.2% in the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock worth $481,000 after buying an additional 29 shares during the last quarter. Savvy Advisors Inc. lifted its holdings in Elevance Health by 3.2% in the fourth quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after acquiring an additional 30 shares during the period. Finally, CoreCap Advisors LLC boosted its holdings in shares of Elevance Health by 6.1% in the fourth quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock worth $195,000 after buying an additional 32 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ELV. Robert W. Baird boosted their price objective on shares of Elevance Health from $331.00 to $393.00 and gave the company a “neutral” rating in a research report on Thursday. Royal Bank Of Canada cut their target price on Elevance Health from $439.00 to $424.00 and set a “sector perform” rating for the company in a research report on Thursday. Truist Financial boosted their price target on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a research note on Tuesday. Jefferies Financial Group lowered their target price on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Finally, Bank of America boosted their target price on Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research report on Thursday, June 4th. Fifteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $439.43.

Elevance Health Stock Down 4.6%

Shares of NYSE ELV opened at $372.20 on Friday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $436.24. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.48 and a current ratio of 1.52. The stock has a 50 day moving average price of $399.65 and a 200 day moving average price of $355.22. The firm has a market capitalization of $80.83 billion, a price-to-earnings ratio of 16.54, a PEG ratio of 2.20 and a beta of 0.67.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating the consensus estimate of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The firm had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. During the same period in the previous year, the company posted $8.84 earnings per share. The firm’s quarterly revenue was up .8% on a year-over-year basis. Sell-side analysts expect that Elevance Health, Inc. will post 27.09 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance Health beat Q2 estimates on both EPS and revenue, with EPS of $7.45 versus expectations around $6.21 and revenue of $49.83 billion topping forecasts. Business Wire release
• Positive Sentiment: The company raised full-year 2026 adjusted EPS guidance to at least $27.00, signaling management sees improving operating performance and better cost control ahead. Reuters article
• Positive Sentiment: Several analysts turned more constructive after the report, with price target increases from firms including Guggenheim, Barclays, Robert W. Baird, and Truist, which can support sentiment on the stock. Benzinga article
• Neutral Sentiment: Recent coverage and earnings-call transcripts highlight improving medical cost management and stronger CarelonRx revenues, but also note ongoing strain in parts of the business and a mixed operating backdrop. Earnings call transcript
• Negative Sentiment: Some reports pointed to margin pressure and softer membership trends, which appear to be weighing on the stock despite the earnings beat. MSN article
• Negative Sentiment: The company is also leaving more Medicaid markets, adding a strategic headwind that may temper enthusiasm about the near-term growth outlook. Yahoo Finance article

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.